Overview

Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

Status:
Completed

Trial end date:
2014-03-07

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of fidaxomicin in pediatric subjects with Clostridium difficile-associated diarrhea (CDAD).

Phase:

Phase 2

Details

Lead Sponsor:

Optimer Pharmaceuticals LLC

Treatments:

Fidaxomicin